Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

112.29
-2.4700-2.15%
Post-market: 112.650.3600+0.32%19:56 EDT
Volume:7.88M
Turnover:892.44M
Market Cap:139.68B
PE:23.74
High:115.54
Open:113.86
Low:111.80
Close:114.76
Loading ...

Trump posts letters calling on drug company CEOs to lower prices

TIPRANKS
·
9 hours ago

Gilead Sciences Advances Pediatric Hepatitis B Treatment with TAF Study Update

TIPRANKS
·
11 hours ago

FDA Approves New Biktarvy Indication for Treatment-Experienced People With HIV Restarting Antiretroviral Therapy, Announces Gilead Sciences Inc

Reuters
·
Yesterday

Gilead Sciences Inc. CEO Daniel O'Day Reports Disposal of Common Shares

Reuters
·
30 Jul

Gilead Sciences Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

Dow Jones
·
30 Jul

Hookipa Pharma Inc. Conducted Special Stockholder Meeting to Vote on Key Proposals

Reuters
·
30 Jul

Gilead Sciences’ Strategic Positioning and Growth Prospects in the HIV Prevention Market Justify Buy Rating

TIPRANKS
·
29 Jul

Why Gilead Sciences Stock Slipped Today

Motley Fool
·
29 Jul

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2025-07-28

Reuters
·
28 Jul

Gilead Sciences Stock Surges Amid Promising Trials

TIPRANKS
·
26 Jul

Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
26 Jul

Why Gilead Sciences Stock Just Popped

Motley Fool
·
26 Jul

Needham Upgrades Gilead Sciences to Buy From Hold, Price Target is $133

MT Newswires Live
·
25 Jul

Gilead upgraded to Buy from Hold at Needham

TIPRANKS
·
25 Jul

Gilead : Needham Raises to Buy From Hold

THOMSON REUTERS
·
25 Jul

Gilead announces CHMP opinion recommending lenacapavir

TIPRANKS
·
25 Jul

Gilead Sciences Receives Positive CHMP Opinion for Twice-Yearly HIV PrEP Lenacapavir, Awaits Final EU Decision

Reuters
·
25 Jul

Gilead Receives Positive Chmp Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for Hiv Prevention

THOMSON REUTERS
·
25 Jul

EU regulator backs Gilead's twice-yearly injection for HIV prevention

Reuters
·
25 Jul

Gilead Sciences Inc. to Release Second Quarter 2025 Financial Results

Reuters
·
25 Jul